Top of this page
Skip navigation, go straight to the content

Investors Overview

we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 

Given the circumstances, we all have had to adapt our ways of working

Thanks to technology (whether Teams, Skype, Zoom or whatever), in the last few weeks, we hosted

over 50 virtual meetings

to keep the contact with you!

Do not hesitate to reach out to us – we are here to help!

IR events

DateEvent details
27 June
Quiet period starts 
27 July
2020 half-year resultsmore details clsoer to the date

2019 integrated report

image description

2019 HY results

image description

Outlook 2020

The closing of the Ra Pharma acquisition led to an update of UCB’s 2020 financial guidance and the mid-term target

The updated financial guidance does not reflect any potential impacts from the evolving COVID-19 pandemic. The company is following these developments diligently to assess the financial significance of this pandemic to UCB

2020 revenue

€ 5.05 - € 5.15 billion 

Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] 

26% - 27%

Core earnings per share

€ 4.40 - € 4.80

based on an average of 187 million shares outstanding


Contact UCB IR team or a specific team member:




UCB IR app available on Apple Store

UCB IR app available on Google Play